-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

BRIEF-Otsuka And Lundbeck Announce U.S. FDA Acceptance And Priority Review Of sNDA For Brexpiprazole For Treatment Of Agitation Associated With Alzheimer's Dementia

Reuters · 01/07/2023 09:45
BRIEF-Otsuka And Lundbeck Announce U.S. FDA Acceptance And Priority Review Of sNDA For Brexpiprazole For Treatment Of Agitation Associated With Alzheimer's Dementia

- Otsuka Corp 4768.T:

  • OTSUKA AND LUNDBECK ANNOUNCE U.S. FDA ACCEPTANCE AND PRIORITY REVIEW OF SNDA FOR BREXPIPRAZOLE FOR TREATMENT OF AGITATION ASSOCIATED WITH ALZHEIMER'S DEMENTIA

Source text for Eikon: ID:

Further company coverage: 4768.T


((Reuters.Briefs@thomsonreuters.com;))